NDAOPHTHALMICGEL
Approved
Oct 2008
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
5/8 — Partial
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTEN is a lidocaine hydrochloride anhydrous ophthalmic gel approved in 2008 for topical anesthetic use in the eye. It provides local anesthesia for ophthalmologic procedures by blocking sodium channels in nerve fibers. The product serves patients requiring ocular anesthesia during diagnostic or minor surgical interventions.
$0.001BPart D
LOE Approaching1mo to LOEMinimal commercial activity with only 14 Part D claims in 2023 signals a niche market with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Thea Pharma is hiring 1 role related to this product
Worked on AKTEN at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.